You are here:
NICE
NICE Guidance
Published Guidance
Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Technology appraisal guidance
Reference number:
TA446
Published:
28 June 2017
This guidance has been updated and replaced by
NICE technology appraisal guidance 524
.